封面
市場調查報告書
商品編碼
1419140

血漿治療市場規模和預測、全球和地區佔有率、趨勢和成長機會分析報告範圍:類型、來源、應用、最終用戶和地理位置

Plasma Therapy Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: Type, Source, Application, End User, and Geography

出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

血漿治療市場預計將從2022年的3.9億美元成長到2030年的10.97億美元;預計2022年至2030年市場CAGR為13.80%。

推動市場成長的關鍵因素包括人們(尤其是老年人口)骨科疾病病例的增加、運動員關節和肌肉損傷數量的增加以及對微創整容手術的需求激增。

富含血小板血漿(PRP)是一種再生醫學,可以放大血液中的天然生長因子來治癒組織。它需要利用從疾病中成功康復的個體獲得的血漿來解決一系列醫療問題並促進康復過程。 PRP 治療可應用於治療關節損傷的骨科、皮膚再生手術以及牙科組織修復

骨科疾病和肌肉損傷病例的增加以及 PRP 在美容手術中的使用增加推動了血漿治療市場的成長

根據世界衛生組織 (WHO) 2023 年發布的統計數據,2019 年全球約有 5.28 億人患有骨關節炎 (OA),較 1990 年增加了 113%。2020 年 12 月發表在 PubMed Central 上的文章指出,由於血漿中含有豐富的生長因子和細胞因子,PRP 的使用提供了組織修復的潛力,這對於啟動和調節軟組織和硬組織的再生微環境至關重要。 PRP療法可用於骨折、韌帶、肌肉和肌腱損傷、週邊神經損傷、關節軟骨損傷和骨關節炎的癒合。因此,骨科和組織修復手術中對血漿療法的需求很高。

此外,PRP也用於美容手術,以實現嫩膚、抗衰老和其他美容手術。 2021 年 11 月 PubMed Central 發表的一篇綜述評估了 73 項研究,其中 45 項研究專注於 PRP 單一療法,而 35 項研究研究了 PRP 與微針聯合治療的效果。因此,這些療法具有良好的耐受性並適合所有光型。多種病症均取得了積極的治療效果,包括皮膚年輕化、疤痕修復、脫髮、色素性疾病、地衣硬化、麻風病引起的周邊神經病變、斑塊狀牛皮癬和指甲疾病。

因此,PRP在整容手術中的使用有助於血漿治療市場的成長。

市場機會

PRP 在合併治療的應用

PRP 療法是一種不斷發展的治療方法,在皮膚科中有多種應用,特別是用於頭髮修復、皮膚年輕化、痤瘡疤痕、真皮增強和擴張皮紋。將 PRP 與雷射療法、微針療法、真皮填充劑和自體脂肪移植結合使用,由於協同效應,可以帶來更好的美容效果。然而,需要針對特定情況對 PRP 治療方案進行標準化。 PRP在皮膚病學領域具有巨大潛力,其治療應用不斷擴大。已經進行了許多研究來評估 PRP 在多種皮膚病(例如雄性禿、白斑和皮膚年輕化)的聯合藥物治療中的效果。例如,PubMed Central 於2021 年發表的一項研究“在雄激素性脫髮的聯合藥物治療中添加富含血小板的血漿的評估”,對126 名患有雄激素性脫髮(AGA) 的患者進行了研究,AGA 是一種常見的脫髮疾病,該研究得出的結論是,將「PRP 與微針」整合到 AGA 的聯合藥物治療中可以提高其療效,並縮短獲得最大改善所需的時間。

同樣,在 Wiley Online Library 於 2020 年 11 月發表的另一篇文章中,進行了一項研究來評估治療白斑症的各種聯合治療策略。該研究包括 11 項研究,670 個病例。結論是,與單一療法相比,結合使用 308 nm 準分子雷射和 PRP 時,色素沉著的臨床改善明顯更高。類似地,點陣二氧化碳雷射和 PRP 的結合導致了更高的平均色素沉著改善程度。

因此,PRP 聯合療法的推出正在為血漿治療市場創造各種機會。

分部概覽

血漿治療市場根據類型、來源、應用、最終產品和最終用戶進行細分。從類型來看,市場分為純PRP、富白血球PRP、純富血小板纖維蛋白及富白血球纖維蛋白。純富含血小板的纖維蛋白細分市場在 2022 年佔據最大的市場佔有率,預計 2022-2030 年CAGR最高。富含白血球的 PRP (LR-PRP) 是一種中性粒細胞(白血球)濃度高於基線水平的 PRP。它通常與促發炎作用有關。然而,在某些情況下,LR-PRP 可能有助於刺激體內炎症,以提示肌腱病等慢性疾病。

血漿治療市場依來源分為自體血漿和同種異體血漿。自體部分在 2022 年佔據市場主導地位,同種異體部分預計在 2022-2030 年期間將錄得更高的CAGR。自體 PRP 注射是一種安全可靠的生物技術,用於治療不同的肌肉骨骼疾病。 PRP注射可透過抑制發炎細胞激素的產生、促進滑膜纖維母細胞的生長,有效支持類風濕性關節炎等慢性自體免疫發炎疾病患者的初級治療。

目錄

第 1 章:簡介

  • 研究範圍
  • 市場定義、假設與限制
  • 市場區隔

第 2 章:執行摘要

  • 重要見解
  • 市場吸引力分析

第 3 章:研究方法

第 4 章:血漿治療市場格局

  • 概述
  • PEST分析

第 5 章:血漿治療市場 - 主要市場動態

  • 主要市場促進因素
  • 主要市場限制
  • 主要市場機會
  • 未來的趨勢
  • 促進因素和限制因素的影響分析

第 6 章:血漿治療市場 - 全球市場分析

  • 血漿治療 - 全球市場概覽
  • 血漿治療 - 全球市場與 2030 年預測

第 7 章:血漿治療市場 - 收入分析 - 按類型,2020-2030 年

  • 概述
  • 純PRP
  • 富含白血球的PRP
  • 純富含血小板的纖維蛋白
  • 富含白血球的纖維蛋白

第 8 章:血漿治療市場 - 收入分析 - 按來源分類,2020-2030 年

  • 概述
  • 自體
  • 同種異體

第 9 章:血漿治療市場 - 收入分析 -按應用,2020-2030 年

  • 概述
  • 骨科
  • 皮膚科
  • 心肌損傷
  • 牙科
  • 神經損傷
  • 其他

第 10 章:血漿治療市場 - 收入分析 - 按最終產品生產,2020-2030 年

  • 概述
  • 白蛋白
  • 免疫球蛋白 G (IgG)
  • 其他

第 11 章:血漿治療市場 - 收入分析 - 按最終用戶,2020-2030 年

  • 概述
  • 醫院和診所
  • 研究機構
  • 門診手術中心

第 12 章:血漿治療市場 - 收入分析,2020-2030 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥

註 - 將為以下提到的地區/國家提供類似的分析

  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 歐洲其他地區
  • 亞太
    • 澳洲
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第 13 章:產業格局

  • 併購
  • 協議、合作、合資企業
  • 新產品發布
  • 擴張和其他策略發展

第14章:競爭格局

  • 關鍵參與者的熱圖分析
  • 公司定位與專注

第 15 章:血漿治療市場 - 主要公司概況

  • BioLife Plasma Services

注意 - 將為以下公司列表提供類似資訊

  • 武田藥品工業株式會社
  • 生物測試公司
  • 中超有限公司
  • 南澳州格里福斯
  • 凱德瑞安公司
  • 免疫泰克生物中心
  • 生物製品實驗室有限公司
  • 中國生物製品控股有限公司
  • 奧克塔製藥公司
  • 起源公司

第 16 章:附錄

  • 詞彙表
  • 關於 Insight Partners
  • 市場情報雲
簡介目錄
Product Code: TIPRE00004429

The plasma therapy market is expected to grow from US$ 390 million in 2022 to US$ 1,097 million by 2030; the market is estimated to register a CAGR of 13.80% from 2022 to 2030.

Key factors driving the market growth include the rising cases of orthopedic disorders in people, especially in the geriatric population, the rising number of joint and muscle injuries in athletes, and the surging demand for minimally invasive cosmetic procedures.

Platelet-rich plasma (PRP) is a form of regenerative medicine that amplifies natural growth factors in blood to heal tissue. It entails the utilization of the blood plasma obtained from individuals who have successfully recovered from an illness to address the range of medical conditions and foster the process of healing. PRP treatments find applications in orthopedics for the treatment of joint injuries, dermatology in skin rejuvenation procedures, and dentistry for tissue repair

Rising Cases of Orthopedic Disorders and muscle Injuries and Increasing Use of PRP in Aesthetic Procedures Drive Plasma Therapy Market Growth

According to statistics published by the World Health Organization (WHO) in 2023, ~528 million people across the world were living with osteoarthritis (OA) in 2019, representing an increase of 113% since 1990. An article published in PubMed Central in December 2020 states that the use of PRP offers potential for tissue repair due to the abundance of growth factors and cytokines in this plasma, which are crucial in initiating and modulating regenerative microenvironments for both soft and hard tissues. PRP therapy can be used in the healing of bone fractures, ligament, muscle, and tendon injuries, peripheral nerve injuries, articular cartilage lesions, and osteoarthritis. Therefore, there is a high demand for plasma therapies in orthopedic and tissue repair procedures.

Moreover, PRP is used in cosmetic surgeries for skin rejuvenation, anti-aging, and other aesthetic procedures. Out of 73 studies evaluated in a review published in PubMed Central in November 2021, 45 studies focused on PRP monotherapy, while 35 studies investigated the effects of PRP in combination with microneedling. As a result, the therapies were well-tolerated and suitable for all phototypes. Positive treatment outcomes were identified for various conditions, including skin rejuvenation, scar revision, alopecia, pigmentary disorders, lichen sclerosis, leprosy-induced peripheral neuropathy, plaque psoriasis, and nail disorders.

Therefore, the use of PRP in cosmetic surgeries contributes to the growth of the plasma therapy market.

Market Opportunity

Use of PRP in Combination Therapies

PRP therapy is an evolving treatment method with several applications in dermatology, particularly for hair restoration, skin rejuvenation, acne scars, dermal augmentation, and striae distensae. Using PRP together with laser therapies, microneedling, dermal fillers, and autologous fat grafting can result in better aesthetic outcomes due to synergistic effects. However, there is a need for standardization of PRP treatment protocols for specific conditions. PRP has great potential in dermatology, and its therapeutic applications are continuously expanding. Many studies have been conducted to assess the effect of PRP in combined medical therapy for various dermatological disorders such as androgenetic alopecia, vitiligo, and skin rejuvenation. For instance, a study, "Evaluation of adding platelet-rich plasma to combined medical therapy in androgenetic alopecia," published by PubMed Central in 2021, was carried out on 126 patients suffering from Androgenetic alopecia (AGA), a common hair loss disorder, the study concluded that the integration of "PRP with micro-needling" to the combined medical therapy in AGA boosts its efficacy and reduces the time required for maximum improvement.

Similarly, in another article published by Wiley Online Library in November 2020, a study was carried out to assess various combination therapy strategies for treating vitiligo. The study included eleven studies with 670 cases. It concluded that in comparison to monotherapy, the clinical improvement of re-pigmentation was significantly higher when using a combination of 308-nm excimer laser and PRP. Similarly, a combination of fractional carbon dioxide laser and PRP resulted in a higher mean improvement grade of re-pigmentation.

Therefore, the introduction of PRP-combination therapies is creating various opportunities in the plasma therapy market.

SEGMENTAL OVERVIEW

The plasma therapy market is segmented on the basis of type, source, application, end product, and end user. In terms of type, the market is segmented into pure PRP, leukocyte-rich PRP, pure platelet-rich fibrin, and leukocyte-rich fibrin. The pure platelet-rich fibrin segment held the largest market share in 2022 and is anticipated to register the highest CAGR during 2022-2030. Leukocyte-rich PRP (LR-PRP) is a type of PRP that has a higher concentration of neutrophils (white blood cells) than the baseline level. It is generally associated with proinflammatory effects. However, in some cases, LR-PRP can be beneficial to stimulate inflammation in the body to indicate a chronic condition such as tendinopathy.

The plasma therapy market, by source, is bifurcated into autologous and allogeneic. The autologous segment dominated the market in 2022, and the allogeneic segment is anticipated to record a higher CAGR during 2022-2030. Autologous PRP injection is a secure and reliable biological technique that is used for the treatment of different musculoskeletal disorders. PRP injection can effectively support the primary treatment of patients with chronic autoimmune inflammatory diseases such as rheumatoid arthritis by suppressing the production of inflammatory cytokines and promoting the growth of synovial fibroblasts.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Plasma Therapy Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Plasma Therapy Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Plasma Therapy Market - Global Market Analysis

  • 6.1 Plasma Therapy - Global Market Overview
  • 6.2 Plasma Therapy - Global Market and Forecast to 2030

7. Plasma Therapy Market - Revenue Analysis (USD Million) - By Type, 2020-2030

  • 7.1 Overview
  • 7.2 Pure PRP
  • 7.3 Leukocyte-Rich PRP
  • 7.4 Pure Platelet-Rich Fibrin
  • 7.5 Leukocyte-Rich Fibrin

8. Plasma Therapy Market - Revenue Analysis (USD Million) - By Source, 2020-2030

  • 8.1 Overview
  • 8.2 Autologous
  • 8.3 Allogenic

9. Plasma Therapy Market - Revenue Analysis (USD Million) - By Application, 2020-2030

  • 9.1 Overview
  • 9.2 Orthopedic
  • 9.3 Dermatology
  • 9.4 Cardiac Muscle Injury
  • 9.5 Dental
  • 9.6 Nerve Injury
  • 9.7 Others

10. Plasma Therapy Market - Revenue Analysis (USD Million) - By End Products Produce , 2020-2030

  • 10.1 Overview
  • 10.2 Albumin
  • 10.3 Immunoglobulin G (IgG)
  • 10.4 Others

11. Plasma Therapy Market - Revenue Analysis (USD Million) - By End User, 2020-2030

  • 11.1 Overview
  • 11.2 Hospitals and Clinics
  • 11.3 Research Institutes
  • 11.4 Ambulatory Surgical Centers

12. Plasma Therapy Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 12.1 North America
    • 12.1.1 North America Plasma Therapy Market Overview
    • 12.1.2 North America Plasma Therapy Market Revenue and Forecasts to 2030
    • 12.1.3 North America Plasma Therapy Market Revenue and Forecasts and Analysis - By Type
    • 12.1.4 North America Plasma Therapy Market Revenue and Forecasts and Analysis - By Source
    • 12.1.5 North America Plasma Therapy Market Revenue and Forecasts and Analysis - By Application
    • 12.1.6 North America Plasma Therapy Market Revenue and Forecasts and Analysis - By End Products Produce
    • 12.1.7 North America Plasma Therapy Market Revenue and Forecasts and Analysis - By End User
    • 12.1.8 North America Plasma Therapy Market Revenue and Forecasts and Analysis - By Countries
      • 12.1.8.1 United States Plasma Therapy Market
        • 12.1.8.1.1 United States Plasma Therapy Market, by Type
        • 12.1.8.1.2 United States Plasma Therapy Market, by Source
        • 12.1.8.1.3 United States Plasma Therapy Market, by Application
        • 12.1.8.1.4 United States Plasma Therapy Market, by End Products Produce
        • 12.1.8.1.5 United States Plasma Therapy Market, by End User
      • 12.1.8.2 Canada Plasma Therapy Market
        • 12.1.8.2.1 Canada Plasma Therapy Market, by Type
        • 12.1.8.2.2 Canada Plasma Therapy Market, by Source
        • 12.1.8.2.3 Canada Plasma Therapy Market, by Application
        • 12.1.8.2.4 Canada Plasma Therapy Market, by End Products Produce
        • 12.1.8.2.5 Canada Plasma Therapy Market, by End User
      • 12.1.8.3 Mexico Plasma Therapy Market
        • 12.1.8.3.1 Mexico Plasma Therapy Market, by Type
        • 12.1.8.3.2 Mexico Plasma Therapy Market, by Source
        • 12.1.8.3.3 Mexico Plasma Therapy Market, by Application
        • 12.1.8.3.4 Mexico Plasma Therapy Market, by End Products Produce
        • 12.1.8.3.5 Mexico Plasma Therapy Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

  • 12.2 Europe
    • 12.2.1 Germany
    • 12.2.2 France
    • 12.2.3 Italy
    • 12.2.4 Spain
    • 12.2.5 United Kingdom
    • 12.2.6 Rest of Europe
  • 12.3 Asia-Pacific
    • 12.3.1 Australia
    • 12.3.2 China
    • 12.3.3 India
    • 12.3.4 Japan
    • 12.3.5 South Korea
    • 12.3.6 Rest of Asia-Pacific
  • 12.4 Middle East and Africa
    • 12.4.1 South Africa
    • 12.4.2 Saudi Arabia
    • 12.4.3 U.A.E
    • 12.4.4 Rest of Middle East and Africa
  • 12.5 South and Central America
    • 12.5.1 Brazil
    • 12.5.2 Argentina
    • 12.5.3 Rest of South and Central America

13. Industry Landscape

  • 13.1 Mergers and Acquisitions
  • 13.2 Agreements, Collaborations, Joint Ventures
  • 13.3 New Product Launches
  • 13.4 Expansions and Other Strategic Developments

14. Competitive Landscape

  • 14.1 Heat Map Analysis by Key Players
  • 14.2 Company Positioning and Concentration

15. Plasma Therapy Market - Key Company Profiles

  • 15.1 BioLife Plasma Services
    • 15.1.1 Key Facts
    • 15.1.2 Business Description
    • 15.1.3 Products and Services
    • 15.1.4 Financial Overview
    • 15.1.5 SWOT Analysis
    • 15.1.6 Key Developments

Note - Similar information would be provided for below list of companies

  • 15.2 Takeda Pharmaceutical Company Limited
  • 15.3 Biotest AG
  • 15.4 CSL Ltd.
  • 15.5 Grifols, S.A.
  • 15.6 Kedrion S.p.A
  • 15.7 ImmunoTek Bio Centers
  • 15.8 Bio Products Laboratory Ltd.
  • 15.9 China Biologic Products Holdings, Inc.
  • 15.10 Octapharma AG
  • 15.11 Origin, Inc.

16. Appendix

  • 16.1 Glossary
  • 16.2 About The Insight Partners
  • 16.3 Market Intelligence Cloud